Home/Alentis Therapeutics/Luigi Manenti

LM

Luigi Manenti

Chief Medical Officer

Alentis Therapeutics

Therapeutic Areas

Oncology Fibrosis

Alentis Therapeutics Pipeline

Drug	Indication	Phase
ALE.P02	Squamous Cancers	Phase 1/2
Lixudebart (ALE.F02)	Organ Fibrosis	Phase 2
ALE.P03	Not Specified	Preclinical

Leadership Team at Alentis Therapeutics

Chief Executive Officer

Prof. Thomas Baumert

View full Alentis Therapeutics profile